title: Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors.
abstract: Exploration of SAR and optimisation of the imidazo[1,2-a]pyridine CDK inhibitors has lead to the discovery of novel, potent and selective inhibitors of the cyclin-dependent kinase CDK2. Understanding of SAR has identified positions of substitution, which allow modification of physical properties and offer the potential for in vivo optimisation.
authors.affiliation: AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
authors.forename: Kate F
authors.initials: KF
authors.lastname: Byth
authors.forename: Janet D
authors.initials: JD
authors.lastname: Culshaw
authors.forename: Stephen
authors.initials: S
authors.lastname: Green
authors.forename: Sandra E
authors.initials: SE
authors.lastname: Oakes
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Thomas
mesh_terms: D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D011725:Pyridines / Q000737:chemistry* / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: D004791:Enzyme Inhibitors; D011725:Pyridines; D018844:Cyclin-Dependent Kinases